Hjem › Mavekreft › North Carolina
Kliniske studier for Mavekreft i North Carolina
21 studier for Mavekreft søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07283939Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07059884Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- og 6 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- University of North Carolina Medical Center, Chapel Hill
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07221149Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07360314A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213791Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Charlotte
- Research Site, Wilmington
- Research Site, Winston-Salem
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07431281Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06750185A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06253871A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Duke Cancer Institute, Durham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07070232A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07749586Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #131, Raleigh
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jul. 2026 · NCT06974110Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05005403A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. jan. 2026 · NCT07317505A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06999187SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT05107674APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. jun. 2025 · NCT03175224Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.